Key result
Aldosterone synthase inhibitors lower blood pressure meaningfully in uncontrolled and resistant hypertension.
Why the study?
Novel aldosterone synthase inhibitors have shown blood pressure reductions in uncontrolled and resistant hypertension, but questions remain about cardiovascular and kidney outcomes, safety, and clinical integration.
What are the clinical evidence, knowledge gaps, and practical considerations for introducing aldosterone synthase inhibitors into clinical practice for hypertension?
What are the clinical evidence, knowledge gaps, and practical considerations for introducing aldosterone synthase inhibitors into clinical practice for hypertension?
As aldosterone synthase inhibitors approach clinical adoption for resistant hypertension, multidisciplinary care models may be necessary to manage their unique safety profile and effects.
Novel therapeutic agents are required to improve hypertension control globally, which remains one of the leading modifiable risk factors for premature cardiovascular mortality. Aldosterone synthase inhibitors (ASIs) are a novel class of agents that suppress aldosterone production and have demonstrated clinically meaningful blood pressure reductions in phase 2 and phase 3 trials in patients with uncontrolled and resistant hypertension. As these therapies approach clinical adoption, important questions remain regarding effects on cardiovascular and kidney outcomes, safety profile, and optimal positioning within existing treatment algorithms. This review synthesizes the current clinical evidence for ASIs, highlights key knowledge gaps, and examines practical considerations for their real-world implementation, including persistent pharmacodynamic effects after treatment withdrawal, short-term changes in glomerular filtration rate, the risk of hyperkalemia, and the potential role of multidisciplinary care models to support safe and effective adoption.
No takes yet. Share an insight, caveat, or question.
Heath et al. (2026) conducted a review in uncontrolled and resistant hypertension. Aldosterone synthase inhibitors (ASIs) was evaluated. Aldosterone synthase inhibitors demonstrate clinically meaningful blood pressure reductions in uncontrolled and resistant hypertension, though long-term cardiovascular and kidney effects remain unknown.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: